PMID- 34093252
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210608
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Electronic)
IS  - 1664-0640 (Linking)
VI  - 12
DP  - 2021
TI  - Development and Internal Validation of a Novel Model to Identify Inflammatory 
      Biomarkers of a Response to Escitalopram in Patients With Major Depressive 
      Disorder.
PG  - 593710
LID - 10.3389/fpsyt.2021.593710 [doi]
LID - 593710
AB  - Objective: The aim of our study was to identify immune- and inflammation-related 
      factors with clinical utility to predict the clinical efficacy of treatment for 
      depression. Study Design: This was a follow-up study. Participants who met the 
      entry criteria were administered with escitalopram (5-10 mg/day) as an initial 
      treatment. Self-evaluation and observer valuations were arranged at the end of 
      weeks 0, 4, 8, and 12, with blood samples collected at baseline and during weeks 
      2 and 12. Multivariable logistic regression analysis was then carried out by 
      incorporating three cytokines selected by the Least Absolute Shrinkage and 
      Selection Operator (LASSO) regression model. Internal validation was estimated 
      using the bootstrap method with 1,000 repetitions. Results: A total of 85 
      patients with Major Depressive Disorder (MDD), including 62 responders and 23 
      non-responders, were analyzed. Monocyte chemoattractant protein-1 (MCP-1), 
      vascular cell adhesion molecule-1 (VCAM-1), and lipocalin-2 were selected by the 
      LASSO regression model. The area under the curve (AUC) from the logistic model 
      was 0.811 and was confirmed as 0.7887 following bootstrapping validation. 
      Conclusions: We established and validated a good prediction model to facilitate 
      the individualized prediction of escitalopram treatment for MDD and created a 
      personalized approach to treatment for patients with depression.
CI  - Copyright (c) 2021 Zhou, Zhou, Sun, Feng, Zhu, Yang and Wang.
FAU - Zhou, Jingjing
AU  - Zhou J
AD  - The National Clinical Research Center for Mental Disorders & Beijing Key 
      Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical 
      University, Beijing, China.
AD  - Advanced Innovation Center for Human Brain Protection, Capital Medical 
      University, Beijing, China.
FAU - Zhou, Jia
AU  - Zhou J
AD  - The National Clinical Research Center for Mental Disorders & Beijing Key 
      Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical 
      University, Beijing, China.
AD  - Advanced Innovation Center for Human Brain Protection, Capital Medical 
      University, Beijing, China.
FAU - Sun, Zuoli
AU  - Sun Z
AD  - The National Clinical Research Center for Mental Disorders & Beijing Key 
      Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical 
      University, Beijing, China.
AD  - Advanced Innovation Center for Human Brain Protection, Capital Medical 
      University, Beijing, China.
FAU - Feng, Lei
AU  - Feng L
AD  - The National Clinical Research Center for Mental Disorders & Beijing Key 
      Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical 
      University, Beijing, China.
AD  - Advanced Innovation Center for Human Brain Protection, Capital Medical 
      University, Beijing, China.
FAU - Zhu, Xuequan
AU  - Zhu X
AD  - The National Clinical Research Center for Mental Disorders & Beijing Key 
      Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical 
      University, Beijing, China.
AD  - Advanced Innovation Center for Human Brain Protection, Capital Medical 
      University, Beijing, China.
FAU - Yang, Jian
AU  - Yang J
AD  - The National Clinical Research Center for Mental Disorders & Beijing Key 
      Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical 
      University, Beijing, China.
AD  - Advanced Innovation Center for Human Brain Protection, Capital Medical 
      University, Beijing, China.
FAU - Wang, Gang
AU  - Wang G
AD  - The National Clinical Research Center for Mental Disorders & Beijing Key 
      Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical 
      University, Beijing, China.
AD  - Advanced Innovation Center for Human Brain Protection, Capital Medical 
      University, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20210520
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC8172985
OTO - NOTNLM
OT  - escitalopram
OT  - followed up study
OT  - inflammatory biomarkers
OT  - major depressive disorder
OT  - predictive model
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/06/08 06:00
MHDA- 2021/06/08 06:01
PMCR- 2021/05/20
CRDT- 2021/06/07 05:49
PHST- 2020/08/11 00:00 [received]
PHST- 2021/04/12 00:00 [accepted]
PHST- 2021/06/07 05:49 [entrez]
PHST- 2021/06/08 06:00 [pubmed]
PHST- 2021/06/08 06:01 [medline]
PHST- 2021/05/20 00:00 [pmc-release]
AID - 10.3389/fpsyt.2021.593710 [doi]
PST - epublish
SO  - Front Psychiatry. 2021 May 20;12:593710. doi: 10.3389/fpsyt.2021.593710. 
      eCollection 2021.